| Ytd | -9.72% | |
| 1y | -7.33% |
| Open | 43.62 | Prev Close | 43.48 | Low | 43.55 | High | 43.84 | Mkt Cap | 104.99B |
| Vol | 256.07K | Avg Vol | 3.41M | EPS | 4.59 | P/E | 9.53 | Forward P/E | 8.16 |
| Beta | 0.35 | Short Ratio | 1.75 | Inst. Own | 8.68% | Dividend | 1.76 | Div Yield | 4.11 |
| Ex Div Date | 05-04 | Earning | 07-30 | 50-d Avg | 43.34 | 200-d Avg | 46.31 | 1yr Est | 54.06 |
President Donald Trump signed an order Monday limiting core childhood vaccine recommendations to 11
https://youtu.be/H_RititNE8U
Sanofi is rated a Buy, with ~33.5% upside to €99.5 fair value (or $57 for SNY ADRs), resulting from
This article is part of our monthly series where we highlight five large-cap, relatively safe, divid
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the d
Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as cri
Sino Biopharma expanded its GSK partnership in China and signed an AstraZeneca licensing deal worth
AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its
Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read
Tracey Beth Hoeg was fired as FDA drug division chief amid a broader Trump administration shake-up a
Novavax shares rise after Q1 revenue beat; partnerships, credit facility, and technical levels shape
Trump, in January, said "inflation has been defeated." Wall Street is now bracing for a 0.9%
Sanofi reports positive Phase 2 data for lunsekimig in asthma and nasal polyps, while atopic dermati
Medicare Chief Chris Klomp is optimistic for strong outcome in the search of CDC leader in midst of
A federal judge warns that RFK Jr.'s vaccine overhaul likely violates federal law. Discover the
FDA grants Breakthrough Therapy status to Rybrevant for advanced cancer while Trellus Health extends
Companies Reporting Before The Bell • Eni (NYSE:E) is expected to report quarterly earnings at $0.7
Energy markets dominated headlines Thursday as a fresh wave of U.S. sanctions targeting Russia's
Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopi
Companies Reporting Before The Bell • Sanofi (NASDAQ:SNY) is projected to report quarterly earnings
Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is expected to report earnings for its f
Companies Reporting Before The Bell • TAL Education (NYSE:TAL) is projected to report quarterly ear
Monday saw 825 companies set new 52-week lows.
On Wednesday, 340 stocks hit new 52-week lows.
On Friday, 109 stocks hit new 52-week lows.
Gainers
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company an
On Thursday, 22 companies reached new 52-week lows.
Companies Reporting Before The Bell • ArcelorMittal (NYSE:MT) is estimated to report earnings fo
Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly
Companies Reporting Before The Bell • PG&E (NYSE:PCG) is likely to report quarterly earnings
On Wednesday, 111 companies set new 52-week highs.
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Highs On Friday
Stocks That Hit 52-Week Highs On Thursday
Stocks That Hit 52-Week Highs On Friday
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Friday
Stocks That Hit 52-Week Highs On Thursday
Benzinga's Top Upgrades, Downgrades For December 1, 2017
Could European Funds Offer An Opportunity Now?